Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

US12208093B2 · kind B2 · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · US

Inventors

• Ravit Boger · Baltimore, US
• Marc Ferrer · Potomac, US
• Juan Jose Marugan · Gaithersburg, US
• Andres Dulcey Garcia · Gaithersburg, US
• Noel Terrence Southall · Bethesda, US
• Xin Hu · Chestertown, US

Key dates

• Filing date: Feb 11, 2022
• Grant date: Jan 28, 2025
• Expiry date: Feb 11, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.